Pathos AI

Executive Summary

Pathos AI is a clinical-stage biotechnology company leveraging artificial intelligence, biological modeling, and extensive oncology patient data to enhance drug development precision. Founded in 2020 and headquartered in New York, the company focuses on identifying optimal patient populations for clinical trials to improve success rates and shorten timelines. Its platform is designed as a scalable, repeatable engine for discovering and developing precision oncology therapies. Currently in Phase 1, Pathos AI aims to address high failure rates in oncology drug development by integrating AI-driven insights from conception through trial execution. The company's approach has the potential to transform how targeted therapies are developed, though it remains early-stage with no disclosed funding or valuation data.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1/2 clinical trial for lead candidate40% success
• Q3 2026Publication of platform validation data in peer-reviewed journal60% success
• Q1 2027Series B financing round or strategic partnership50% success